<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03025698</url>
  </required_header>
  <id_info>
    <org_study_id>CETB115E2201</org_study_id>
    <nct_id>NCT03025698</nct_id>
  </id_info>
  <brief_title>A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia</brief_title>
  <official_title>A Phase II, Open-label, Non-controlled, Intra-patient Dose-escalation Study to Characterize the Pharmacokinetics After Oral Administration of Eltrombopag in Pediatric Patients With Refractory, Relapsed or Treatment Naive Severe Aplastic Anemia or Recurrent Aplastic Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II, open label, multi-center, intra-patient dose escalation study to
      characterize the pharmacokinetics after oral administration of eltrombopag in combination
      with immunosuppressive therapy in pediatric patients with previously untreated or
      relapsed/refractory severe aplastic anemia or recurrent aplastic anemia.

      All patients will be treated with eltrombopag for the 26-week Treatment Period, followed by a
      52-week Follow-Up Period. Patients who have been previously untreated with immunosuppressive
      therapy will be treated according to the standard of care, hATG/cyclosporine, in addition to
      eltrombopag. Patients with relapsed/refractory SAA or recurrent AA will be enrolled into one
      of two treatment options: hATG/cyclosporine plus eltrombopag or cyclosporine plus
      eltrombopag, depending on prior treatment with immunosuppressive therapy.

      After initiating treatment with eltrombopag, patients will have their dose assessed and
      modified as tolerated, until the targeted platelet count or maximum dose is achieved.
      Pharmacokinetic assessments will be performed at time points intended to capture steady state
      PK of the starting dose and highest dose achieved.

      Upon completion of the Treatment and Follow-Up Periods, all patients will be offered the
      opportunity to enroll in an additional 3 year Long Term Follow-Up Period.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 30, 2017</start_date>
  <completion_date type="Anticipated">August 30, 2027</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Eltrombopag PK parameter: AUCtau</measure>
    <time_frame>2 weeks and 12 weeks after dose initiation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Eltrombopag PK parameter: Cmax</measure>
    <time_frame>2 weeks and 12 weeks after dose initiation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Eltrombopag PK parameter: Ctrough</measure>
    <time_frame>2 weeks and 12 weeks after dose initiation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with an overall response (OR)</measure>
    <time_frame>Week 12, Week 26, Week 52, and Week 78.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with a platelet response.</measure>
    <time_frame>Week 12, Week 26, Week 52, and Week 78.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clonal chromosomal population in bone marrow, myelodysplasia by morphology or acute leukemia</measure>
    <time_frame>Week 12, Week 26, Week 52 and Week 78.</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Aplastic Anemia</condition>
  <arm_group>
    <arm_group_label>Cohort A (Option 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A (option 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eltrombopag</intervention_name>
    <description>Tablet for oral use, once daily</description>
    <arm_group_label>Cohort A (Option 1)</arm_group_label>
    <arm_group_label>Cohort A (option 2)</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hATG</intervention_name>
    <description>Horse ATG (ATGAM) (hATG) is not considered an investigational medicinal product (IMP)</description>
    <arm_group_label>Cohort A (Option 1)</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CsA</intervention_name>
    <description>Cyclosporine (CsA) will be by supplied as either oral capsules or oral solution, administered twice a day</description>
    <arm_group_label>Cohort A (Option 1)</arm_group_label>
    <arm_group_label>Cohort A (option 2)</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For Cohort A:

          1. Prior history of diagnosis of SAA

          2. Diagnosis of relapsed/refractory SAA or recurrent AA following IST for SAA at the time
             of enrollment. Patients with recurrent AA (e.g., losing their response) are exempt
             from meeting the diagnostic criteria for relapsed SAA at the time of enrollment, but
             must have been previously diagnosed with SAA.

          3. Agree to concurrent eltrombopag treatment with appropriate, investigator-selected IST
             with either hATG + CsA or CsA.

             For Cohort B:

          4. Diagnosis of SAA at the time of enrollment

          5. Patients must not have been previously treated for SAA

          6. Patients must agree to treatment with hATG + CsA concurrent with eltrombopag.

             For all patients, regardless of cohort:

          7. Age 1 to &lt;18 years

          8. Where appropriate, assessments to rule out congenital/inherited bone marrow failure
             syndromes and other causes of immune-mediated pancytopenia, which may be treated with
             transplant, must be completed prior to enrollment.

          9. Hematopoietic stem cell transplantation (HSCT) is not available or suitable as a
             treatment option or has been refused by the patient. (Candidacy for HSCT will be
             determined as per local practice.)

         10. Bone marrow aspirate and biopsy at any time during the 4 weeks prior to first dose of
             eltrombopag

         11. Normal karyotype with FISH for chromosomes 7 and 8

         12. Performance status score: Karnofsky ≥50 or Lansky ≥50 (depending on age)

         13. Serum creatinine ≤2.5 × ULN

         14. Total bilirubin ≤1.5 × ULN

         15. Written informed consent signed by a parent or legal guardian prior to initiation of
             any study specific procedure.

        Exclusion Criteria:

          1. Prior and/or active medical history of:

               -  Fanconi anemia (via chromosomal breakage test or growth arrest by flow cytometry)

               -  Other known underlying congenital/inherited marrow failure syndromes

               -  Symptomatic Paroxysmal Nocturnal Hemoglobinuria (PNH) and/or PNH clones &gt;50% of
                  PMN or RBC at time of enrollment

               -  Any cytogenetic abnormalities, including but not limited to chromosome 7 or
                  myelodysplasia, in bone marrow within 4 weeks of study enrollment

               -  Myelodysplastic syndrome (MDS)

               -  Other known or suspected underlying primary immunodeficiency

               -  Any malignancy

          2. Active infection not responding to appropriate therapy

          3. Prior eltrombopag or other thrombopoietin receptor (TPO-R) agonist treatment for at
             least 2 months and a lack of response.

          4. Any out of range lab values Creatinine &gt;2.5 × upper limit of normal (ULN), Total
             bilirubin &gt;1.5 × ULN Aspartate aminotransferase (AST) or alanine aminotransferase
             (ALT) &gt;2.5 × ULN
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Phoenix Children's Hospital SC</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>602-933-0171</phone>
    </contact>
    <investigator>
      <last_name>Jessica Boklan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arkansas Childrens Hospital SC</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suzy Hall</last_name>
      <phone>501-364-4181</phone>
      <email>Hallsf@ARchildrens.org</email>
    </contact>
    <investigator>
      <last_name>Jason Farrar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California-UCSF SC</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-0780</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>415-514-1489</phone>
    </contact>
    <investigator>
      <last_name>James Huang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Childrens Hospital Colorado</last_name>
      <phone>720-777-6353</phone>
      <email>IDS@childrenscolorado.org</email>
    </contact>
    <investigator>
      <last_name>Taizo Nakano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida Shands SC</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610-0486</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joshua Drug Terrell</last_name>
      <phone>352-273-9050</phone>
      <email>jterrell5102@ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Paul Castillo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aflac Cancer and Blood Disorders Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabrielle Dean</last_name>
      <phone>404-785-2025</phone>
      <email>Gabrielle.Dean@choa.org</email>
    </contact>
    <investigator>
      <last_name>Carolyn Bennett</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ann and Robert H Lurie Childrens Hospital of Chicago SC</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trecia Dawkins</last_name>
      <phone>312-227-4825</phone>
      <email>TMalcolm@luriechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Alexis Thompson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University SC Riley Children's Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202-5225</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital of Boston SC</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health System SC</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ciara L. Viola</last_name>
      <phone>734-936-1854</phone>
      <email>cjviola@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Kelly Walkovich</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center SC-2</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center SC</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hai Huang</last_name>
      <email>h.hai@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Jennifer Rothman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Cleveland Clinic (5)</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Nationwide Childrens Hospital SC</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heidi Ziegler</last_name>
      <phone>614-722-6885</phone>
      <email>heidi.ziegler@nationwidechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Melissa Rose</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital of Philadelphia SC-2</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104 4399</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beverly Paul</last_name>
      <phone>267-426-9989</phone>
      <email>paul@email.chop.edu</email>
    </contact>
    <investigator>
      <last_name>Timothy Olson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburg School of Medicines</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalie Thurman</last_name>
      <email>Natalie.thurman2@chp.edu</email>
    </contact>
    <investigator>
      <last_name>Steven Allen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center SC</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol Mendrygal</last_name>
      <email>CAROL.Mendrygal@childrens.com</email>
    </contact>
    <investigator>
      <last_name>Kathryn Dickerson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Children's Cancer and Hematology Center SC</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allison R Damron</last_name>
      <phone>832-824-4825</phone>
      <email>rxmiller@texaschildrens.org</email>
    </contact>
    <investigator>
      <last_name>Alison Bertuch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Childrens Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospital SC</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberta Johnson</last_name>
      <phone>608-890-8070</phone>
      <email>rjjohnson@pediatrics.wisc.edu</email>
    </contact>
    <investigator>
      <last_name>Inga Hofmann</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shatin</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Utrecht</city>
        <state>CS</state>
        <zip>3584</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lisboa</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Porto</city>
        <zip>4099-001</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Porto</city>
        <zip>4200 319</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454076</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>117198</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok noi</city>
        <state>Bangkok</state>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Khon Kaen</city>
        <state>THA</state>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>WC1N 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Hong Kong</country>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Thailand</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 12, 2017</study_first_submitted>
  <study_first_submitted_qc>January 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2017</study_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Eltrombopag</keyword>
  <keyword>hATG</keyword>
  <keyword>CsA</keyword>
  <keyword>previously untreated or relapsed severe aplastic anemia</keyword>
  <keyword>recurrent aplastic anemia</keyword>
  <keyword>Severe aplastic anemia</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Immunosuppressive therapy</keyword>
  <keyword>ETB115</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

